To delineate the consequences of the sustained IFNα secretion induced by infliximab, we compared the proportion of circulating CD19+CD20-CD38+ plasma cells in RA ANA-positive patients (n = 10) and RA ANA-negative patients (n = 10). This evidence concerns the gene CD38 and rheumatoid arthritis.